The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Bogolepova A.N.

Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency

Features of pharmacotherapy of vascular cognitive impairment in the elderly

Authors:

Bogolepova A.N.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(9): 15‑20

DOI: 10.17116/jnevro202312309115

Read: 2159 times

Download PDF (RU)
Contact the author
Table of contents

FEATURES OF PHARMACOTHERAPY OF VASCULAR COGNITIVE IMPAIRMENT IN THE ELDERLY
FEATURES OF PHARMACOTHERAPY OF VASCULAR COGNITIVE IMPAIRMENT IN THE ELDERLY

To cite this article:

Bogolepova AN. Features of pharmacotherapy of vascular cognitive impairment in the elderly. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(9):15‑20. (In Russ.)
https://doi.org/10.17116/jnevro202312309115

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Modern approaches to diagnosis and treatment of syndrome of auto­nomic dysfunction in children. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11-2):66-75
Modern aspe­cts of chro­nic cere­bral ischemia pathogenetic therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):106-113
Arte­rial hype­rtension is an oxidative stress, as a pathogenetic target for the treatment of chro­nic cere­brovascular insu­fficiency. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):84-90
The effect of Mexi­dol on the level of neurogenesis markers in acute cere­brovascular acci­dent in the expe­riment. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):107-112
Personal characteristics of patients with cere­bral microangiopathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):51-56
Modern approaches to diagnosis and treatment of postinfectious asthenic syndrome in children. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):42-52
The main mechanisms of deve­lopment of cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):13-18
The known and new ideas about the mechanism of action and the spectrum of effe­cts of Mexi­dol. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):22-33
Treatment features of patients with vascular cognitive impairments. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):69-76
Treatment of acute postoperative pain and prevention of chro­nic postoperative pain syndrome. Piro­gov Russian Journal of Surgery. 2024;(12):81-86
Abstract:

The problem of pharmacotherapy of elderly and senile people is currently extremely relevant due to the aging of the population and the increase in the prevalence of cardiovascular diseases. One of the most serious problems of the elderly is the development of cognitive decline due to cerebrovascular pathology. However, elderly patients often have a large number of comorbid diseases, which leads to difficulties in diagnosing and managing these patients, and often to the development of polypharmacy, which can lead to deterioration in functional status, cognitive impairment, adverse reactions and drug interactions. In addition, in elderly patients, there may be changes in pharmacokinetics and pharmacodynamics due to anatomical and physiological involutive processes. At the same time, the number of drugs whose clinical efficacy and tolerability were evaluated specifically in elderly and senile patients is relatively small. In a randomized clinical trial of sequential parenteral and oral therapy with Mexidol in patients with mild vascular cognitive impairment syndrome, a positive effect of this therapy on various domains (cognitive, emotional, autonomic, motor) of chronic cerebrovascular disease was confirmed compared with placebo, which allows us to recommend it for use in elderly and senile patients.

Keywords:

vascular cognitive impairment
elderly patient
pharmacotherapy
ethylmethylhydroxyperidine succinate
Mexidol

Authors:

Bogolepova A.N.

Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency

Received:

01.06.2023

Accepted:

18.07.2023

Close metadata

References:

  1. United Nations, Department of Economic and Social Affairs, Population Division () World Population Prospects 2019: Highlights, United Nations, New York. 2019. Link is available 20.04.23.  https://population.un.org/wpp/publications/files/wpp2019_highlights.pdf
  2. Krivanek TJ, Gale SA, McFeeley BM, et al. Promoting Successful Cognitive Aging: A Ten-Year Update. J Alzheimers Dis. 2021;81(3):871-920.  https://doi.org/10.3233/JAD-201462
  3. Cai Y, Song W, Li J, et al. The landscape of aging. Sci China Life Sci. 2022;65(12):2354-2454. https://doi.org/10.1007/s11427-022-2161-3
  4. Rizzi L, Rosset I, Roriz-Cruz M. Global epidemiology of dementia: Alzheimer’s and vascular types. Biomed Res Int. 2014;2014:908915. https://doi.org/10.1155/2014/908915
  5. Chan KY, Wang W, Wu JJ, et al; Global Health Epidemiology Reference Group (GHERG). Epidemiology of Alzheimer’s disease and other forms of dementia in China, 1990-2010: a systematic review and analysis. Lancet. 2013;381:2016-2023. https://doi.org/10.1016/S0140-6736(13)60221-4
  6. Jia L, Du Y, Chu L, et al; COAST Group. Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study. Lancet Public Health. 2020;5(12):661-671.  https://doi.org/10.1016/S2468-2667(20)30185-7
  7. Kuźma E, Lourida I, Moore SF, et al. Stroke and dementia risk: a systematic review and meta-analysis. Alzheimers Dement. 2018;14:1416-1426. https://doi.org/10.1016/j.jalz.2018.06.3061
  8. Pendlebury ST, Rothwell PM. Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. Lancet Neurol. 2009;8:1006-1018. https://doi.org/10.1016/S1474-4422(09)70236-4
  9. Pendlebury ST, Rothwell PM; Oxford Vascular Study. Incidence and prevalence of dementia associated with transient ischaemic attack and stroke: analysis of the population-based oxford vascular study. Lancet Neurol. 2019;18:248-258.  https://doi.org/10.1016/S1474-4422(18)30442-3
  10. Portegies ML, Wolters FJ, Hofman A, et al. Prestroke vascular pathology and the risk of recurrent stroke and poststroke dementia. Stroke. 2016;47:2119-2122. https://doi.org/10.1161/STROKEAHA.116.014094
  11. Mok VC, Lam BY, Wong A, et al. Early-onset and delayed-onset poststroke dementia — revisiting the mechanisms. Nat Rev Neurol. 2017;13:148-159.  https://doi.org/10.1038/nrneurol.2017.16
  12. Wolters FJ, Ikram MA. Epidemiology of Vascular Dementia. Arterioscler Thromb Vasc Biol. 2019;39(8):1542-1549. https://doi.org/10.1161/ATVBAHA.119.311908
  13. Boyle PA, Yu L, Wilson RS, et al. Person-specific contribution of neuropathologies to cognitive loss in old age. Ann Neurol. 2018;83:74-83.  https://doi.org/10.1002/ana.25123
  14. Ossenkoppele R, Jansen WJ, Rabinovici GD, et al; Amyloid PET Study Group. Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA. 2015;313:1939-1949. https://doi.org/10.1001/jama.2015.4669
  15. Wen W, Sachdev PS, Li JJ, et al. White matter hyperintensities in the forties: their prevalence and topography in an epidemiological sample aged 44—48. Hum Brain Mapp. 2009;30(4):1155-1167. https://doi.org/10.1002/hbm.20586
  16. de Leeuw FE, de Groot JC, Achten E, et al. Prevalence of cerebral white matter lesions in elderly people: a population based magnetic resonance imaging study. The Rotterdam Scan Study. J Neurol Neurosurg Psychiatry. 2001;70(1):9-14.  https://doi.org/10.1136/jnnp.70.1.9
  17. Vermeer SE, Longstreth WT, Koudstaal PJ. Silent brain infarcts: a systematic review. Lancet Neurol. 2007;6(7):611-619.  https://doi.org/10.1016/S1474-4422(07)70170-9
  18. Vermeer SE, Prins ND, den Heijer T, et al. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med. 2003;348(13):1215-1222. https://doi.org/10.1056/NEJMoa022066
  19. Debette S, Beiser A, DeCarli C, et al. Association of MRI markers of vascular brain injury with incident stroke, mild cognitive impairment, dementia, and mortality: the Framingham Offspring Study. Stroke. 2010;41(4):600-606.  https://doi.org/10.1161/STROKEAHA.109.570044
  20. Boyle PA, Wang T, Yu L, et al. To what degree is late life cognitive decline driven by age-related neuropathologies? Brain. 2021;144(7):2166-2175. https://doi.org/10.1093/brain/awab092
  21. Borders C, Sajjadi SA. Diagnosis and Management of Cognitive Concerns in the Oldest-Old. Curr Treat Options Neurol. 2021;23(3):10.  https://doi.org/10.1007/s11940-021-00665-5
  22. Michalowsky B, Hoffmann W, Kostev K. Association between hearing and vision impairment and risk of dementia: results of a case-control study based on secondary data. Front Aging Neurosci. 2019;11:363.  https://doi.org/10.3389/fnagi.2019.00363
  23. Tuunainen E, Poe D, Jäntti P, et al. Presbyequilibrium in the oldest old, a combination of vestibular, oculomotor and postural deficits. Aging Clin Exp Res. 2011;23:364-371. 
  24. Jeng Y, Young Y. Evolution of vestibular disorders in older adults: from young-old to middle-old to oldest-old. Geriatr Gerontol Int. 2020;20:42-46.  https://doi.org/10.1111/ggi.13813
  25. Lipsitz LA, Manor B, Habtemariam D, et al. The pace and prognosis of peripheral sensory loss in advanced age: association with gait speed and falls. BMC Geriatr. 2018;18:274.  https://doi.org/10.1186/s12877-018-0970-5
  26. Hao Q, Dong B, Yang M, et al. Frailty and cognitive impairment in predicting mortality among oldest-old people. Front Aging Neurosci. 2018;10:295.  https://doi.org/10.3389/fnagi.2018.00295
  27. Lee DR, Kawas CH, Gibbs L, Corrada MM. Prevalence of frailty and factors associated with frailty in individuals aged 90 and older: the 90+ study. J Am Geriatr Soc. 2016;64:2257-2262. https://doi.org/10.1111/jgs.14317
  28. Boyle PA, Buchman AS, Wilson RS, et al. Physical frailty is associated with incident mild cognitive impairment in community-based older persons. J Am Geriatr Soc. 2010;58:248-255.  https://doi.org/10.1111/j.1532-5415.2009.02671.x
  29. Jacobs JM, Cohen A, Ein-Mor E, et al. Frailty, cognitive impairment and mortality among the oldest old. J Nutr Health Aging. 2011;15:678-682.  https://doi.org/10.1007/s12603-011-0096-3
  30. Held FP, Blyth F, Gnjidic D, et al. Association Rules Analysis of Comorbidity and Multimorbidity: The Concord Health and Aging in Men Project. J Gerontol A Biol Sci Med Sci. 2016;71(5):625-631.  https://doi.org/10.1093/gerona/glv181
  31. Barnett K, Mercer SW, Norbury M, et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012;380(9836):37-43.  https://doi.org/10.1016/S0140-6736(12)60240-2
  32. Ushkalova EA, Tkacheva ON, Runikhina NK, et al. Features of pharmacotherapy in elderly patients. Introduction to the problem. Rational pharmacotherapy in cardiology. 2016;12(1):94-100. (In Russ.). https://doi.org/10.20996/1819-6446-2016-12-1-94-100
  33. Lai X, Zhu H, Huo X, Li Z. Polypharmacy in the oldest old (≥80 years of age) patients in China: a cross-sectional study. BMC Geriatr. 2018;18:64.  https://doi.org/10.1186/s12877-018-0754-y
  34. Wauters M, Elseviers M, Vaes B, et al. Polypharmacy in a Belgian cohort of community-dwelling oldest old (80+) Acta Clin Belg. 2016;71:158-166.  https://doi.org/10.1080/17843286.2016.1148298
  35. Dwyer LL, Han B, Woodwell DA, Rechtsteiner EA. Polypharmacy in nursing home residents in the United States: results of the 2004 National Nursing Home Survey. Am J Geriatr Pharmacother. 2010;8:63-72.  https://doi.org/10.1016/j.amjopharm.2010.01.001
  36. Bronskill SE, Gill SS, Paterson JM, et al. Exploring variation in rates of polypharmacy across long term care homes. J Am Med Dir Assoc. 2012;13(3):309.e15-21.  https://doi.org/10.1016/j.jamda.2011.07.001
  37. Wang R, Chen L, Fan L, et al. Incidence and effects of polypharmacy on clinical outcome among patients aged 80+: a five-year follow-up study. PLoS One. 2015;10:e0142123. https://doi.org/10.1371/journal.pone.0142123
  38. Safronenko AV, Gantsgorn EV, Safronenko VA, et al. Peculiarities of pharmacotherapy of patients of elderly and senile age. South Russian Journal of Therapeutic Practice. 2021;2(4):6-15. (In Russ.). https://doi.org/10.21886/2712-8156-2021-2-4-6-15
  39. Akazawa M, Imai H, Igarashi A, Tsutani K. Potentially inappropriate medication use in elderly Japanese patients. Am J Geriatr Pharmacother. 2010;8:146-160.  https://doi.org/10.1016/j.amjopharm.2010.03.005
  40. Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014;13:57-65.  https://doi.org/10.1517/14740338.2013.827660
  41. Bourgeois FT, Shannon MW, Valim C, Mandl KD. Adverse drug events in the outpatient setting: an 11-year national analysis. Pharmacoepidemiol Drug Saf. 2010;19:901-910.  https://doi.org/10.1002/pds.1984
  42. Hohl CM, Dankoff J, Colacone A, Afilalo M. Polypharmacy, adverse drug-related events, and potential adverse drug interactions in elderly patients presenting to an emergency department. Ann Emerg Med. 2001;38:666-671.  https://doi.org/10.1067/mem.2001.119456
  43. Methodological guide «Pharmacotherapy in the elderly and senile age» of the Ministry of Health of the Russian Federation 2018 ID: MP103. (In Russ.).
  44. Lee VW, Pang KK, Hui KC, et al. Medication adherence: is it a hidden drug-related problem in hidden elderly? Geriatr Gerontol Int. 2013;13:978-985.  https://doi.org/10.1111/ggi.12042
  45. General principles of pharmacotherapy in elderly and senile patients. Guidelines. Ed. Tkacheva O.N. M.: Prometheus; 2019. (In Russ.).
  46. Cherubini A, Oristrell J, Pla X, et al. The persistent exclusion of older patients from ongoing clinical trials regarding heart failure. Arch Intern Med. 2011;171(6):550-556.  https://doi.org/10.1001/archinternmed.2011.31
  47. Stern Y, Arenaza-Urquijo EM, Bartres-Faz D, et al. Whitepaper: defining and investigating cognitive reserve, brain reserve, and brain maintenance. Alzheimers Dement. 2020;16(9):1305-1311. https://doi.org/10.1016/j.jalz.2018.07.219
  48. Arenaza-Urquijo EM, Vemuri P. Resistance vs resilience to Alzheimer disease: clarifying terminology for preclinical studies. Neurology. 2018;90(15):695-703.  https://doi.org/10.1212/WNL.0000000000005303
  49. Pettigrew C, Soldan A. Defining Cognitive Reserve and Implications for Cognitive Aging. Curr Neurol Neurosci Rep. 2019;19(1):1-10.  https://doi.org/10.1007/s11910-019-0917-z
  50. Bogolepova AN. The role of oxidative stress in the development of vascular cognitive disorders. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2020;120(8):133-139. (In Russ.). https://doi.org/10.17116/jnevro2020120081133
  51. Chukanova EI, Chukanova AS. Efficacy and safety of the drug mexidol FORTE 250 as part of sequential therapy in patients with chronic ischemia of the brain. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2019;119(9):39-45. (In Russ.). https://doi.org/10.17116/jnevro201911909139
  52. https://doi.org/10.17116/jnevro20211211117  https://doi.org/10.17116/jnevro20211211117
  53. Zakharov VV, Tkacheva ON, Mkhitaryan EA, Fedin AI. Efficacy of Mexidol in patients with chronic brain ischemia and cognitive impairment of different age groups (results of sub-analysis of the international multicenter, randomized, double-blind, placebo-controlled study of sequential therapy in patients with chronic brain ischemia MEMO). Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2022;122(11 vyp 2):73-80. (In Russ.). https://doi.org/10.17116/jnevro202212211273
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.